Phaseline

Companies › HealthTech Wound Care

HealthTech Wound Care: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 4; Metabolic and endocrine.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DermaBind TL
Full-thickness dehydrated placental allograft
–Phase 4Diabetic Foot Ulcer (DFU)–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07172893DermaBind TLPhase 4Diabetic Foot Ulcer (DFU)Metabolic and endocrineOct 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

PolarityTE Royal Biologics Ascendis Pharma Bone Diseases BioXTek Blue Blood Biotech

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.